BIO

Dr. Ingmar Gorman is a licensed psychologist specializing in helping individuals navigate anxiety, depression, trauma, substance use, and psychedelic experiences. With a deep understanding of the challenges faced by highly geographically mobile individuals and business leaders—gained through both personal and professional experience—Dr. Gorman offers tailored support to clients managing complex lives and transitions.

In addition to his expertise in traditional psychotherapy, Dr. Gorman is a recognized leader in the field of psychedelic therapy. As a cofounder of Fluence, a leading psychedelic education company, he has dedicated his career to training mental health providers and sharing his knowledge with clients and trainees alike.

Dr. Gorman brings firsthand experience from his role as site co-principal investigator on an FDA-approved Phase 3 clinical trial of MDMA-Assisted Psychotherapy for Post-Traumatic Stress Disorder. And as a study therapist in the same trial and in another groundbreaking clinical study of psilocybin for treatment-resistant depression. His clinical work is informed by his extensive research and publication record, which includes topics such as classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.

Trained in New York City, Dr. Gorman completed his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He further honed his expertise during an NIH postdoctoral fellowship at New York University.